Fabry Disease Screening in High-risk Populations in Japan: a Nationwide Study

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2020 Aug 27

PMID 32843101

Citations 8

Authors

Shinichiro Yoshida

Jun Kido

Takaaki Sawada

Ken Momosaki

Keishin Sugawara

Shirou Matsumoto

Fumio Endo

Kimitoshi Nakamura

Affiliations

Soon will be listed here.

Abstract

Background: Fabry disease (FD) is a X-linked inherited disorder caused by mutations in the GLA gene, which results in the deficiency of α-galactosidase A (α-Gal A). This leads to the progressive accumulation of metabolites, which can cause multisystemic dysfunction. A recent screening study among neonates reported an increase in the incidence of FD, and numerous FD patients remain undiagnosed or even misdiagnosed. Therefore, this study aimed to identify patients with FD by performing high-risk screening in 18,135 individuals, enrolled from October 2006 to March 2019, with renal, cardiac, or neurological manifestations from all prefectures in Japan. A total of 601 hospitals participated in this study.

Results: Low α-Gal A activity was detected in 846 individuals, with 224 of them diagnosed with FD by GLA sequencing. Cases with a family history of FD (n = 64) were also subjected to sequencing, without α-Gal A assay, as per individual request, and 12 of them were diagnosed with a variant of FD. A total of 236 patients with FD (97 males and 139 females) were identified from among 18,199 participants. A total of 101 GLA variants, including 26 novel variants, were detected in the 236 patients with FD from 143 families, with 39 amenable variants (39%) and 79 of the 236 patients (33%) suitable for migalastat treatment.

Conclusions: From among 18,199 participants, 101 GLA variants, including 26 novel variants, were identified in the 236 patients with FD from 143 families. Migalastat was identified as a suitable treatment option in 33% of the patients with FD and 39% of the GLA variants were detected as amenable. Therefore, the simple screening protocol using dried blood spots that was performed in this study could be useful for early diagnosis and selection of appropriate treatments for FD in high-risk and underdiagnosed patients with various renal, cardiac, or neurological manifestations.

Citing Articles

Clinical characteristics of female Fabry disease patients with hypertrophic cardiomyopathy with mid-ventricular obstruction.

Inagaki N, Takei Y, Hatano T, Takada Y, Yazaki Y, Kosuge H Mol Genet Metab Rep. 2025; 42:101196.

PMID: 39995634 PMC: 11849635. DOI: 10.1016/j.ymgmr.2025.101196.

Late-onset renal variant Fabry disease with R112H mutation and mild increase in plasma globotriaosylsphingosine: a case report.

Tanaka K, Sugiyama H, Morinaga H, Onishi A, Tanabe K, Uchida H Front Med (Lausanne). 2024; 11:1383309.

PMID: 38903807 PMC: 11187088. DOI: 10.3389/fmed.2024.1383309.

Fabry disease and sleep disorders: a systematic review.

Blaszczyk B, Wieckiewicz M, Kusztal M, Michalek-Zrabkowska M, Lachowicz G, Mazur G Front Neurol. 2023; 14:1217618.

PMID: 37869133 PMC: 10586315. DOI: 10.3389/fneur.2023.1217618.

Gene therapy for lysosomal storage diseases: Current clinical trial prospects.

Kido J, Sugawara K, Nakamura K Front Genet. 2023; 14:1064924.

PMID: 36713078 PMC: 9880060. DOI: 10.3389/fgene.2023.1064924.

High-risk screening for Fabry disease in hemodialysis patients in Chiba Prefecture, Japan.

Imasawa T, Murayama K, Sawada T, Hirose M, Takayanagi M, Nakamura K Clin Exp Nephrol. 2022; 27(3):288-294.

PMID: 36574104 DOI: 10.1007/s10157-022-02295-w.

References

Froissart R, Guffon N, Vanier M, Desnick R, Maire I . Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003; 80(3):307-14. DOI: 10.1016/S1096-7192(03)00136-7. View

Romani I, Borsini W, Nencini P, Morrone A, Ferri L, Frusconi S . De novo Diagnosis of Fabry Disease among Italian Adults with Acute Ischemic Stroke or Transient Ischemic Attack. J Stroke Cerebrovasc Dis. 2015; 24(11):2588-95. DOI: 10.1016/j.jstrokecerebrovasdis.2015.07.012. View

HALDANE J . The rate of spontaneous mutation of a human gene. 1935. J Genet. 2005; 83(3):235-44. DOI: 10.1007/BF02717892. View

Landrum M, Lee J, Benson M, Brown G, Chao C, Chitipiralla S . ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2015; 44(D1):D862-8. PMC: 4702865. DOI: 10.1093/nar/gkv1222. View

Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-75. PMC: 1734754. DOI: 10.1136/jmg.38.11.769. View

Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M . Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet. 2003; 40(8):e103. PMC: 1735554. DOI: 10.1136/jmg.40.8.e103. View

Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U . Fabry disease: a review of current management strategies. QJM. 2010; 103(9):641-59. DOI: 10.1093/qjmed/hcq117. View

Waldek S, Patel M, Banikazemi M, Lemay R, Lee P . Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009; 11(11):790-6. DOI: 10.1097/GIM.0b013e3181bb05bb. View

Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G . Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2016; 3:21-7. PMC: 4750577. DOI: 10.1016/j.ymgmr.2015.02.002. View

10.

Kong X, Zhong X, Liu L, Cui S, Yang Y, Kong L . Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy. BMC Med Genet. 2019; 20(1):139. PMC: 6694523. DOI: 10.1186/s12881-019-0873-0. View

11.

Ishii S, Nakao S, Minamikawa-Tachino R, Desnick R, Fan J . Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet. 2002; 70(4):994-1002. PMC: 379133. DOI: 10.1086/339431. View

12.

Nakamura K, Hattori K, Endo F . Newborn screening for lysosomal storage disorders. Am J Med Genet C Semin Med Genet. 2011; 157C(1):63-71. DOI: 10.1002/ajmg.c.30291. View

13.

Lu Y, Huang P, Wang L, Hsu T, Li H, Lee P . Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet. 2017; 63(1):1-8. DOI: 10.1038/s10038-017-0366-y. View

14.

van der Tol L, Verhamme C, van Schaik I, van der Kooi A, Hollak C, Biegstraaten M . In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease. JIMD Rep. 2015; 28:95-103. PMC: 5059210. DOI: 10.1007/8904_2015_503. View

15.

Kobayashi M, Ohashi T, Iizuka S, Kaneshiro E, Higuchi T, Eto Y . Frequency of mutations in Japanese patients with Fabry disease. Mol Genet Metab Rep. 2016; 1:283-287. PMC: 5121308. DOI: 10.1016/j.ymgmr.2014.07.001. View

16.

Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G . Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006; 95(1):86-92. DOI: 10.1080/08035250500275022. View

17.

Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T . Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020; 22:100562. PMC: 6961758. DOI: 10.1016/j.ymgmr.2019.100562. View

18.

Linthorst G, Poorthuis B, Hollak C . Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol. 2008; 51(21):2082. DOI: 10.1016/j.jacc.2008.02.050. View

19.

Tsukimura T, Nakano S, Togawa T, Tanaka T, Saito S, Ohno K . Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease. Mol Genet Metab Rep. 2016; 1:288-298. PMC: 5121323. DOI: 10.1016/j.ymgmr.2014.07.005. View

20.

Liao H, Hsu T, Young L, Chiang C, Huang C, Liu H . Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan. Mol Genet Metab. 2017; 123(2):140-147. DOI: 10.1016/j.ymgme.2017.06.002. View